Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Reconstruction of Lateral Skull Base Defects
Howard, Brittany E. , Nagel, Thomas H. , Barrs, David M., Donald, Carrlene B., Hayden, Richard E.

Otolaryngology–Head and Neck Surgery | March 15, 2016 | Volume: 154 | Issue: 6 | Pages: 1014-1018

10.1177/0194599816634296 | PMID 26980913 Get It

ObjectivesTo compare reconstructive techniques, operative times, duration of hospitalization, and need for subsequent flap revisions between reconstructive approaches to lateral skull base defects.Study DesignCase series with chart review.SettingTertiary academic referral center.SubjectsPatients (n = 31) undergoing reconstruction of composite lateral skull base defects from 2002 to 2014.MethodsData were analyzed for demographics, tumor characteristics, reconstructive technique, operative time, duration of hospitalization, complications, and outcomes.ResultsThirty‐one patients were identified for inclusion. Lateral temporal bone defects resulted from resection of malignant lesions, including squamous cell carcinoma (n = 25), basal cell carcinoma (n = 2), and other carcinoma (n = 4). Defects were reconstructed with submental flaps (n = 16), pedicled latissimus dorsi flaps (n = 6), and free anterolateral thigh flaps (n = 9). All cases involved neurosurgery, neurotology, and head and neck surgery services. Although time of surgical resection was similar, time saving was noticed with submental reconstruction. Compared with free flaps, submental flap reconstruction was associated with significantly reduced total operative time (mean, 544 vs 683 min; P =. 00817) and duration of hospitalization (4.9 vs 9.8 days; P =. 02067). Submental flaps were significantly less likely to require revision debulking procedures (mean = 0.6) compared with latissimus dorsi flaps (mean, 1.3; P <. 00001) and free flaps (mean, 1.6; P <. 00001). There was 100% flap survival.ConclusionThe musculocutaneous submental flap provides an excellent option for reconstruction of lateral skull base defects given its proximity, reliability, ease of harvest, and exceptional color match. Submental flap reconstruction was associated with reduced operative time, hospitalization duration, and flap revisions.
Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease
Schott, Jonathan M. , Crutch, Sebastian J. , Carrasquillo, Minerva M., Uphill, James, Shakespeare, Timothy J. , Ryan, Natalie S. , Yong, Keir , Lehmann, Manja , Ertekin‐Taner, Nilüfer , Graff‐Radford, Neill R., Murray, Melissa E. , Khan, Qurat ul Ain , Petersen, Ronald C., Rabinovici, Gil D. , González, Aida Suárez, Gil-Néciga, E, Snowden, Julie S. , Pickering‐Brown, Stuart , Louwersheimer, Eva, Flier, Wiesje M. van der , Scheltens, Philip , Pijnenburg, Yolande A.L. , Galasko, Douglas, Sarazin, Marie , Dubois, Bruno , Magnin, Éloi , Galimberti, Daniela , Scarpini, Elio , Cappa, Stefano F. , Hodges, John R. , Halliday, Glenda M. , Bartley, Lauren, Carrillo, María C. , Brás, José , Hardy, John , Rossor, Martin N. , Collinge, John, Fox, Nick C. , Mead, Simon , Carrasquillo, Minerva M. , Graff‐Radford, Neill R. , Boeve, Bradley F. , Dickson, Dennis W. , Knopman, David S. , Miller, Bruce L. , Gonzalez, Aida Suarez , Harris, Jenny , Halliday, Glenda , Murray, Melissa E , Hardy, John , van der Flier, Wiesje M , Scheltens, Philip , Fox, Nick C , Yong, Keir X X , Rabinovici, Gil D , Schott, Jonathan M , Galimberti, Daniela , Pijnenburg, Yolande A L

Alzheimer's & Dementia | March 15, 2016 | Volume: 12 | Issue: 8 | Pages: 862-871

10.1016/j.jalz.2016.01.010 | PMID 26993346 Get It

AbstractIntroductionThe genetics underlying posterior cortical atrophy (PCA), typically a rare variant of Alzheimer's disease (AD), remain uncertain.MethodsWe genotyped 302 PCA patients from 11 centers, calculated risk at 24 loci for AD/DLB and performed an exploratory genome‐wide association study.ResultsWe confirm that variation in/near APOE/TOMM40 (P = 6 × 10−14) alters PCA risk, but with smaller effect than for typical AD (PCA: odds ratio [OR] = 2.03, typical AD: OR = 2.83, P = .0007). We found evidence for risk in/near CR1 (P = 7 × 10−4), ABCA7 (P = .02) and BIN1 (P = .04). ORs at variants near INPP5D and NME8 did not overlap between PCA and typical AD. Exploratory genome‐wide association studies confirmed APOE and identified three novel loci: rs76854344 near CNTNAP5 (P = 8 × 10−10 OR = 1.9 [1.5–2.3]); rs72907046 near FAM46A (P = 1 × 10−9 OR = 3.2 [2.1–4.9]); and rs2525776 near SEMA3C (P = 1 × 10−8, OR = 3.3 [2.1–5.1]).DiscussionWe provide evidence for genetic risk factors specifically related to PCA. We identify three candidate loci that, if replicated, may provide insights into selective vulnerability and phenotypic diversity in AD.
Primary sclerosing cholangitis
Silveira, Marina G., Lindor, Keith D.

Canadian Journal of Gastroenterology | March 15, 2016 | Volume: 22 | Issue: 8 | Pages: 689-698

10.1155/2008/824168 | PMID 18701947 Get It

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts, resulting in end-stage liver disease and reduced life expectancy. PSC primarily affects young and middle-aged men, often in association with underlying inflammatory bowel disease. The etiology of PSC includes immune-mediated components and elements of undefined nature. A cholestatic picture of liver biochemistries with elevations in serum alkaline phosphatase, nonspecific autoantibodies such as perinuclear antineutrophilic antibody, antinuclear antibodies and smooth muscle antibodies, and diffuse multifocal biliary strictures, resulting in a ‘beaded’ appearance on radiographic studies, are the hallmarks of the disease. No effective medical therapy is currently available, although clinical studies are in progress. Ursodeoxycholic acid at high doses (28 mg/kg/day to 30 mg/kg/day) is the most promising agent but is unproven so far. Liver transplantation is currently the only life-extending therapy for patients with end-stage disease, although recurrent disease can be observed in the transplanted liver. The multiple complications of PSC include pruritus, fatigue, vitamin deficiencies, metabolic bone disease, peristomal varices, bacterial cholangitis, dominant biliary strictures, gallbladder stones and polyps, and malignancy, particularly cholangiocarcinoma, which is the most lethal complication of PSC.
Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial
Loftus, Edward V. , Binion, David G. , Chen, Naijun, Guérette, B., Mulani, Parvez, Chao, Jingdong, Panaccione, Remo , McHugh, Kevin J. , Alam, Shamsul , Loftus, Edward V

Canadian Journal of Gastroenterology | March 15, 2016 | Volume: 25 | Issue: 8 | Pages: 419-425

10.1155/2011/724813 | PMID 21912766 Get It

OBJECTIVE: To evaluate open-label adalimumab therapy for clinical effectiveness, fistula healing, patient-reported outcomes and safety in Canadian patients with moderate to severe Crohn’s disease (CD) who were either naive to or previously exposed to antitumour necrosis factor (anti-TNF) therapy.METHODS: Patients with moderate to severe CD (CD activity index [CDAI] score of greater than 220, or Harvey-Bradshaw index [HBI] of 7 or greater) were eligible. Patients received open-label adalimumab as induction (160 mg and 80 mg subcutaneously [sc]) at weeks 0 and 2, respectively and maintenance (40 mg sc every other week) therapy. At or after eight weeks, patients with flare or nonresponse could have their dosage increased to 40 mg sc weekly. Patients were followed for a minimum of six months or until adalimumab was commercially available in Canada.RESULTS: Of the 304 patients enrolled, 160 were infliximab experienced, while 144 were anti-TNF naive. HBI remission (HBI score of 4 or lower) at week 24 was achieved by 53% of anti-TNF-naive and 36% of infliximab-experienced patients (P<0.01; P<0.001 for both groups for all visits versus baseline). Fistula healing rates at week 12 were 48% for anti-TNF-naive patients, and 26% for infliximab-experienced patients. At week 24, fistula healing rates were significantly greater for the anti-TNF-naive group (60% versus 28%; P<0.01). Improvements in quality of life and work productivity were sustained from week 4 to week 24 for all patients. Serious infections occurred in 2% of patients.CONCLUSIONS: Adalimumab therapy induced and sustained steroid-free remission in both infliximab-experienced and anti-TNF-naive patients with moderate to severe CD. Clinically meaningful rates of fistula healing were also observed. Improvements in patient-reported outcomes were sustained throughout the 24-week study period.
Challenges in the Diagnosis and Management of Autoimmune Hepatitis
Czaja, Albert J.

Canadian Journal of Gastroenterology | March 15, 2016 | Volume: 27 | Issue: 9 | Pages: 531-539

10.1155/2013/981086 | PMID 24078938 Get It

BACKGROUND: Autoimmune hepatitis has diverse clinical phenotypes and outcomes that challenge current diagnostic criteria and management algorithms.OBJECTIVES: To highlight the major difficulties in diagnosis and management, describe the efforts to ease them and encourage further progress in problem solving.METHODS: The MEDLINE database was reviewed for published experiences from 1984 to 2013.RESULTS: Acute or acute severe (fulminant) hepatitis, asymptomatic mild disease, and histological findings of centrilobular necrosis or bile duct injury can confound diagnosis and treatment. Continuation of conventional therapy until normal liver test results and liver tissue reduces the frequency of relapse, but does not prevent its occurrence. Problematic patients can be identified using mathematical models, clinical phenotype, serological markers and the speed of improvement after treatment; however, their recognition and treatment are inconsistent. Mycophenolate mofetil can rescue patients with azathioprine intolerance but is less effective for refractory disease. Budesonide in combination with azathioprine can be used frontline, but is effective primarily in noncirrhotic, uncomplicated disease. Molecular and cellular interventions are feasible but largely unevaluated.DISCUSSION: Resolution of the current challenges requires revision of diagnostic criteria, characterization of biological markers that reflect pathogenic pathways, development of dynamic indexes based on changes in disease behaviour, and introduction of new pharmacological, molecular and cellular interventions that have undergone rigorous evaluation.CONCLUSION: These challenges reflect important remediable deficiencies in current management.
Diffuse Pulmonary Lymphangiomatosis
Kadakia, Kunal C. , Patel, Sandeep M. , Yi, Eunhee S. , Limper, Andrew H.

Canadian Respiratory Journal | March 15, 2016 | Volume: 20 | Issue: 1 | Pages: 52-54

10.1155/2013/971350 | PMID 23457676 Get It

Diffuse pulmonary lymphangiomatosis (DPL) is a rare disease characterized by infiltration of the lung, pleura and mediastinum with thin-walled lymphangiomas. DPL can result in mass effect from infiltrative disease, restrictive and obstructive pulmonary physiology, chylous effusions and respiratory failure. The present article discusses clinical, radiographic and pathological features, and treatment options for DPL.
Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial
Hanauer, Stephen B., Sandborn, William J. , Dallaire, Christian, Archambault, André, Yacyshyn, Bruce , Yeh, Chyon, Smith-Hall, Nancy

Canadian Journal of Gastroenterology | March 15, 2016 | Volume: 21 | Issue: 12 | Pages: 827-834

10.1155/2007/862917 | PMID 18080055 Get It

BACKGROUND: Delayed-release oral mesalamine 2.4 g/day to 4.8 g/day has been shown to be effective in treating mildly to moderately active ulcerative colitis (UC), but it is unknown whether an initial dose of 4.8 g/day is more effective than 2.4 g/day in patients with mildly to moderately active UC and in the subgroup with moderate disease.PATIENTS AND METHODS: A six-week, multicentre, randomized, double-blind, controlled trial assessing the safety and clinical efficacy of a new dose (ASCEND I) of medication randomly assigned 301 adults with mildly to moderately active UC to delayed-release oral mesalamine 2.4 g/day (400 mg tablet [n=154]) or 4.8 g/day (800 mg tablet [n=147]). The primary efficacy end point was overall improvement (ie, treatment success), defined as complete remission or response to therapy from baseline to week 6. Primary safety end points were adverse events and laboratory evaluations. Data were also analyzed separately for the prespecified subgroup of patients with moderate UC at baseline.RESULTS: Treatment success was not statistically different between the treatment groups at week 6; 51% of the group (77 of 150) who received delayed-release oral mesalamine 2.4 g/day and 56% of the group (76 of 136) who received 4.8 g/day reached the efficacy end point (P=0.441). Among the moderate disease subgroup, however, the higher initial dose was more effective; 57% of patients (53 of 93) given delayed-release oral mesalamine 2.4 g/day and 72% of patients (55 of 76) given 4.8 g/day achieved treatment success (P=0.0384). Both regimens were well tolerated.CONCLUSIONS: Delayed-release oral mesalamine is an effective and well-tolerated initial therapy in patients with mildly to moderately active UC, and a 4.8 g/day dose may enhance treatment success rates in patients with moderate disease compared with mesalamine 2.4 g/day.
Autoimmune Hepatitis: Focusing on Treatments other than Steroids
Czaja, Albert J.

Canadian Journal of Gastroenterology | March 15, 2016 | Volume: 26 | Issue: 9 | Pages: 615-620

10.1155/2012/512132 | PMID 22993733 Get It

BACKGROUND: Corticosteroid therapy has been the time-honoured treatment for autoimmune hepatitis; however, the emergence of new immunosuppressive agents has afforded opportunities to improve or replace the standard regimens. OBJECTIVE: To describe technological advances and feasible treatment interventions that promise to supplant the current generation of corticosteroids. METHODS: A review of the MEDLINE database for published experiences from 1984 to 2011 was conducted. RESULTS: Cyclosporine and tacrolimus have been uniformly successful as salvage therapies for steroid-refractory autoimmune hepatitis. Ten reports of cyclosporine therapy involving 133 patients had positive outcomes in 93%, whereas therapy with tacrolimus in three reports involving 41 patients had positive outcomes in 98%. Salvage therapy with mycophenolate mofetil had a favourable outcome in 47%, especially in patients with azathioprine intolerance. Front-line therapy with mycophenolate mofetil normalized liver parameters in 88% and allowed corticosteroid tapering in 58%. Front-line therapy with budesonide combined with azathioprine for six months normalized liver parameters more frequently (47% versus 18%) and with fewer side effects (28% versus 53%) than prednisone combined with azathioprine. Monoclonal antibodies to CD3 and recombinant cytotoxic T lymphocyte antigen 4 fused with immunoglobulin represent feasible molecular interventions for study in autoimmune hepatitis. DISCUSSION: Nonstandard drug therapies must be used in highly selected clinical situations including steroid failure (calcineurin inhibitors), azathioprine intolerance (mycophenolate mofetil), and mild disease or fragile patients (budesonide combined with azathioprine). Molecular interventions for autoimmune hepatitis are feasible for study because of their use in other immune-mediated diseases. CONCLUSION: Opportunities to improve or replace standard corticosteroid regimens have emerged.
Diagnosis and Management of the Overlap Syndromes of Autoimmune Hepatitis
Czaja, Albert J.

Canadian Journal of Gastroenterology | March 15, 2016 | Volume: 27 | Issue: 7 | Pages: 417-423

10.1155/2013/198070 | PMID 23862175 Get It

BACKGROUND: Autoimmune hepatitis may have cholestatic features that are outside the classical phenotype and that resemble findings in other immune-mediated liver diseases. These cholestatic phenotypes have been designated ‘overlap syndromes’. OBJECTIVES: To recognize the overlap syndromes in adults and manage them appropriately. METHODS: The MEDLINE database was reviewed for published experiences from 1984 to 2013. RESULTS: Patients with autoimmune hepatitis may exhibit features of primary biliary cirrhosis (7% to 13%), primary sclerosing cholangitis (6% to 11%) or a cholestatic syndrome without other diagnostic features (5% to 11%). These mixed phenotypes may represent classical autoimmune hepatitis with atypical features, transition states in the evolution of classical cholestatic syndromes, concurrent separate diseases or pathogenically distinct disorders. The ‘Paris criteria’ have been endorsed for the diagnosis of the overlap syndrome with primary biliary cirrhosis, and treatment with conventional immunosuppressive therapy alone or in combination with low-dose ursodeoxycholic acid can be guided by the serum alkaline phosphatase level. The overlap syndrome with primary sclerosing cholangitis or with cholestasis without diagnostic features is commonly treated with immunosuppressive therapy and ursodeoxycholic acid. Responses are variable and commonly incomplete (20% to 100% improvement) depending on the degree of cholestasis. DISCUSSION: The overlap syndromes are clinical descriptions rather than pathological entities, and the dominant component of the disease determines its designation and therapy. Cholestatic findings in autoimmune hepatitis influence the response to immunosuppressive therapy. CONCLUSION: The overlap syndromes must be considered in patients with autoimmune hepatitis and cholestatic findings, concurrent inflammatory bowel disease or steroid-refractory disease.
Precision medicine: opportunities, possibilities, and challenges for patients and providers
Adams, Samantha , Petersen, Carolyn , Petersen, Carolyn

Journal of the American Medical Informatics Association | March 15, 2016 | Volume: 23 | Issue: 4 | Pages: 787-790

10.1093/jamia/ocv215 | PMID 26977101 Get It

AbstractPrecision medicine approaches disease treatment and prevention by taking patients’ individual variability in genes, environment, and lifestyle into account. Although the ideas underlying precision medicine are not new, opportunities for its more widespread use in practice have been enhanced by the development of large-scale databases, new methods for categorizing and representing patients, and computational tools for analyzing large datasets. New research methods may create uncertainty for both healthcare professionals and patients. In such situations, frameworks that address ethical, legal, and social challenges can be instrumental for facilitating trust between patients and providers, but must protect patients while not stifling progress or overburdening healthcare professionals. In this perspective, we outline several ethical, legal, and social issues related to the Precision Medicine Initiative’s proposed changes to current institutions, values, and frameworks. This piece is not an exhaustive overview, but is intended to highlight areas meriting further study and action, so that precision medicine’s goal of facilitating systematic learning and research at the point of care does not overshadow healthcare’s goal of providing care to patients.